IART - Integra Lifesciences Holdings Corporation (IART) Shareholders Should Contact Robbins LLP for Information About the Class Action Allegations Against Integra Lifesciences Holdings Corporation | Benzinga

SAN DIEGO, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons or entities that purchased or otherwise acquired Integra Lifesciences Holdings Corporation (NASDAQ:IART) common stock between March 11, 2019 and May 22, 2023. Integra develops regenerative tissue technologies and neurological solutions.

For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What is this Case About: Integra Lifesciences Holdings Corporation (IART) Misled Investors Regarding the Remediation of Violations at its Boston Facility

According to the complaint, during the class period, defendants assured investors it was making improvements to remediate violations in its Boston Facility as noted by the FDA and touted the progress of its SurgiMend product to be used in implant-based breast reconstruction.

However, Integra had failed to take sufficient measures to remediate the violations identified by the FDA. Moreover, the Company was not making progress towards obtaining its premarket approval (PMA) indication for SurgiMend, in part, because the Boston Facility was ...

IART) Shareholders Should Contact Robbins LLP for Information About the Class Action Allegations Against Integra Lifesciences Holdings Corporation>Full story available on Benzinga.com